Aspira Women's Health Inc. (AWHL)

Market Cap	17.84M +557.2%
Revenue (ttm)	8.90M -4.3%
Net Income	-10.25M
EPS	-0.33
Shares Out	43.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,024
Open	0.4200
Previous Close	0.4200
Day's Range	0.3631 - 0.4200
52-Week Range	0.0420 - 0.7100
Beta	1.88
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Aspira Women's Health

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; and OvaWatch, a assist in the initial and periodic clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OVAinform, a multi-marker test tha...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1993
• Employees: 36
• Stock Exchange: OTCMKTS
• Ticker Symbol: AWHL

Financial Performance

In 2025, Aspira Women's Health's revenue was $9.22 million, an increase of 0.37% compared to the previous year's $9.18 million. Losses were -$12.78 million, -2.40% less than in 2024.